KAI Pharmaceuticals
KAI Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at KAI Pharmaceuticals.
KAI Pharmaceuticals is a company.
Key people at KAI Pharmaceuticals.
Key people at KAI Pharmaceuticals.
KAI Pharmaceuticals was a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in treatments for cardiovascular and kidney diseases.[2][4] It developed peptide-based therapies, including its lead candidate etelcalcetide (KAI-4169), a calcimimetic for chronic kidney disease-mineral bone disorder (CKD-MBD) and secondary hyperparathyroidism, which reached approval in the European Union in November 2016.[1][5] The company addressed unmet needs in renal and cardiovascular conditions through mechanisms like CaSR agonists, with a pipeline including delcasertib for infarction and others in pending phases; it served patients with hyperparathyroidism, spinal cord injuries, and perioperative ischemia.[1] KAI operated with around 15 employees until its acquisition by Amgen in 2012, marking the end of its independent growth.[3][4]
KAI Pharmaceuticals emerged as a biotech focused on innovative peptide drugs for serious diseases, though specific founding year and founders are not detailed in available records.[1][2] Its early traction centered on advancing KAI-4169 into clinical trials starting around 2011-2012, targeting CKD-MBD, alongside other candidates like KAI-1678 for spinal cord injuries.[1][5] A pivotal moment came in July 2012 when Amgen acquired the privately held company, integrating its pipeline—particularly the promising etelcalcetide—into Amgen's broader renal portfolio.[3][5] This acquisition highlighted KAI's rapid progress from development to strategic value in under a decade of operation.[2]
KAI stood out in the biopharma space through its specialized pipeline and technology:
KAI rode the early 2010s wave of peptide therapeutics and calcimimetics in nephrology, addressing rising chronic kidney disease burdens amid aging populations and dialysis growth.[1][5] Timing was ideal post-2000s biotech boom, when renal drugs like etelcalcetide filled voids left by first-generation therapies, influencing Amgen's dominance in CKD-MBD markets.[3] Market forces like increasing end-stage renal disease prevalence (driven by diabetes and hypertension) favored its pipeline, while its acquisition exemplified how small biotechs fuel big pharma innovation—transferring 8 patents, trials, and literature to amplify ecosystem impact in cardiovascular-renal therapies.[1][2]
Post-2012 acquisition, KAI's legacy endures through etelcalcetide, now commercialized by Amgen as Parsabiv for secondary hyperparathyroidism, with ongoing global approvals and use in dialysis patients.[1][3] Next steps involve Amgen expanding its applications amid trends like precision nephrology and combo therapies for CKD. Evolving biosimilars and AI-driven drug design could challenge it, but KAI's foundational peptides position Amgen to shape renal care, underscoring how nimble biotechs like KAI accelerate breakthroughs in high-need diseases.[1][5]
